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Drug Information Question

Question: What evidence is available on apixaban (Eliquis®) for the primary
prevention of stroke in patients with atrial fibrillation?
by Justin Dang, Pharm.D.  Candidate, Class of 2013, and Laura Tsu, Pharm.D., Assistant Professor, Midwestern
University College of Pharmacy-Glendale

Answer:
Introduction
Atrial fibrillation is a type of supraventricular tachycardia
where the atria beat at rates of 400-600 beats/minute and have
disorganized atrial activation. Common symptoms of atrial
fibrillation include tachycardia, palpitations, and worsening of
heart failure symptoms. Approximately 2.2 million Americans
have atrial fibrillation and it is expected to increase to 12-15
million by 2050. The prevalence of atrial fibrillation increases
with age, severity of heart failure, and other cardiovascular
disease states.1
Atrial fibrillation increases the risk of stroke due to atrial
stasis and thrombi formation.1 The American College of Chest
Physicians (ACCP) recommends assessing the stroke risk in
patients with atrial fibrillation using the CHADS2 scoring system.
Patients are given two points if they have had a prior stroke or
transient ischemic attack and one point each if they are > 75
years of age or have hypertension, diabetes, or congestive heart
failure.2 The risk of stroke increases for each additional point in
the CHADS2 score with a 1.9% risk for a score of 0, 2.8% for
a score of 1, 4.0% for a score of 2, 5.9% for a score of 3, 8.5%
for a score of 4, 12.5% for a score of 5, and 18.2% for a score of
6.3 Aspirin can reduce the risk of stroke by 21% compared to no
therapy, and warfarin can reduce the risk of stroke by one-half
compared to aspirin. The ACCP guidelines recommend that
patients with a score of 0, indicating low risk, should receive no
therapy, aspirin (75 - 325 mg/day), or aspirin plus clopidogrel.
Patients with a CHADS2 score of one, indicating intermediate
risk, should receive oral anticoagulation over aspirin or aspirin
plus clopidogrel. Lastly, patients with a CHADS2 score of two or
greater, indicating high risk, should receive oral anticoagulation.2
Despite the proven efficacy of warfarin and aspirin,
recommendations for oral anticoagulation now favor the newer
oral anticoagulants over warfarin. These novel anticoagulants
have shown at least equal efficacy to warfarin in preventing
stroke and systemic embolism in patients with atrial fibrillation,
but lack warfarin’s limitations, which include a narrow
therapeutic window, need for frequent monitoring, multiple drugdrug interactions, and dietary restrictions (especially foods with
high vitamin K content). Currently, the ACCP guidelines give
a higher recommendation to dabigatran, an oral direct thrombin
inhibitor, over warfarin. Other emerging oral anticoagulants
include the factor Xa inhibitors, rivaroxaban and apixaban,
which target a common point in both the extrinsic and intrinsic
pathways of the clotting cascade and a primary site for signal
amplification.4 Factor Xa inhibitors also have the advantage of
not needing international normalized ratio (INR) monitoring
and having fewer drug and food interactions than vitamin K
antagonists, such as warfarin.2,4
The latest factor Xa inhibitor, apixaban, is currently not
FDA-approved, but two completed trials have demonstrated
apixaban’s safety and efficacy compared to aspirin and warfarin
in preventing stroke and systemic embolism in patients with atrial
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fibrillation. In addition, three completed trials have demonstrated
apixaban’s safety and efficacy compared to enoxaparin in patients
undergoing elective total knee replacement and hip replacement
surgery, and three ongoing trials are currently investigating
apixaban’s role in venous thromboembolism (VTE) prophylaxis
and treatment.5 Apixaban is currently dosed at 2.5 or 5 mg twice
daily with maximum concentration reached in 1-3 hours for
stroke prevention in patients with atrial fibrillation. Apixaban
is approximately 25% renally excreted and 15% metabolized by
CYP3A4. In clinical trials, apixaban has shown no significant
drug-drug interactions and no adverse effects beyond bleeding.5
In a search of Medline, two randomized controlled clinical
trials have investigated the safety and efficacy of apixaban for
stroke and systemic embolism prevention in patients with atrial
fibrillation.6,7
Clinical Trials
The AVERROES (Apixaban Versus Acetylsalicylic Acid [ASA]
to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed
or Are Unsuitable for Vitamin K Antagonist Treatment) trial by
Connolly et al. compares apixaban 5 mg twice daily with aspirin
at a dose of 81 to 324 mg daily. A reduced dose of apixaban
was used (2.5 mg twice daily) if patients met at least two of the
following criteria: ≥ 80 years old, weight ≤ 60 kg, or SCr ≥ 1.5
mg/dL. The investigators estimated that a total of 5600 patients
would be needed to have 90% power to detect a 35% relative
reduction in events, as compared to aspirin. The trial randomized
5599 patients with atrial fibrillation who were not taking a
vitamin K antagonist because it was unsuitable or expected to
be unsuitable and had at least one risk factor for stroke: prior
stroke or transient ischemic attack, age > 75 years, hypertension,
diabetes mellitus, heart failure (New York Heart Association
class II or higher), left ventricular ejection fraction < 35%, or
documented peripheral arterial disease. The primary efficacy
outcome was the occurrence of stroke (ischemic or hemorrhagic)
or systemic embolism. The primary safety outcome was the
occurrence of major bleeding as defined by the International
Society of Thrombosis and Haemostasis (ISTH), which includes
a decrease in hemoglobin level of ≥ 2 g/dL over a 24-hour period,
transfusion of ≥ 2 packed red blood cells, bleeding at a critical
site, or fatal bleeding.6
The results of this trial showed 51 primary outcome events
(1.6% per year) for patients on apixaban and 113 events (3.7%
per year) for patients on aspirin (95% CI, 0.32 to 0.62; P<0.001).
The rate of death was 3.5% per year for patients on apixaban
and 4.4% per year for patients on aspirin (95% CI, 0.62 to
1.02; P=0.07). There were 44 major bleeding events (1.4% per
year) for patients on apixaban and 39 events (1.2% per year)
for patients on apixaban (95% CI, 0.74 to 1.75; P=0.57). There
were 188 minor bleeding events for patients on apixaban and 153
events for patients on aspirin (95% CI, 1.00 to 1.53; P=0.05).
The composite rate of stroke, systemic embolism, myocardial
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infarction, death from vascular causes, or major bleeding was
5.3% per year with apixaban and 7.2% per year with aspirin (95%
CI, 0.60 to 0.90; P=0.003). The trial was terminated early for
efficacy after the first planned interim analysis and confirmatory
analysis showed a benefit with apixaban over 4 SD (z=4.76) and
P value of 0.000002. The authors of this study concluded that
apixaban reduced the risk of stroke or systemic embolism by
more than 50% when compared with aspirin without significantly
increasing the risk of major bleeding.6
The ARISTOTLE (Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation) trial by
Granger et al. compares apixaban 5 mg twice a day with doseadjusted warfarin to INR of 2-3. Similar to the AVERROES
trial, a reduced dose of apixaban was used (2.5 mg twice daily) if
patients met at least two of the following criteria: ≥ 80 years old,
weight ≤ 60 kg, or SCr ≥1.5 mg/dL. The investigators estimated
that 18,000 patients would be needed to achieve 90% power to
show at least a 50% relative risk reduction in stroke and systemic
embolism compared with warfarin. The trial randomized 18,201
patients with atrial fibrillation and at least one other risk factor
for stroke: prior stroke, transient ischemic attack, or systemic
embolism; age over 75 years; hypertension (receiving treatment);
symptomatic heart failure; or left ventricular ejection fraction less
than 40%. The primary efficacy outcome was stroke or systemic
embolism, and the key secondary efficacy outcome was death
from any cause. The primary safety outcome was major bleeding
as defined by ISTH criteria.7
The results of the trial showed the primary outcome occurring
in 212 patients (1.27% per year) in the apixaban group and 265
patients (1.60% per year) in the warfarin group (95% CI, 0.66 to
0.95; P<0.001 for noninferiority and P=0.01 for superiority). The
rate of death from any cause was 3.52% per year in the apixaban
group and 3.94% per year in the warfarin group (P=0.047).
Major bleeding occurred in 327 patients (2.13% per year) in the
apixaban group and 462 patients (3.09% per year) in the warfarin
group. This includes a lower rate of intracranial hemorrhage with
apixaban versus warfarin (52 versus 122, P<0.001). The authors
of this study concluded that apixaban significantly reduced the
risk of stroke or systemic embolism by 21%, major bleeding by
31%, and death by 11% compared with dose-adjusted warfarin.7

atrial fibrillation and showed no difference in the rates of major
bleeding. The lower dose of dabigatran 110 mg twice daily was
non-inferior to warfarin with respect to prevention of stroke or
systemic embolism and had a significantly lower incidence of
major bleeding.8 In the ROCKET AF (Rivaroxaban Once Daily
Oral Direct Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation) trial, rivaroxaban 20 mg was non-inferior to
warfarin in terms of stroke and systemic embolism prevention,
but there were similar rates of major bleeding between the
two groups.9 This is in comparison to apixaban, which has
demonstrated superiority in preventing stroke and systemic
embolism compared to warfarin, without a corresponding
increase in major bleeding. However, it is not possible to state
that apixaban is the preferred anticoagulant because while the
ARISTOTLE, RE-LY, and ROCKET-AF trials shared similar
primary efficacy and safety endpoints, the patient populations
were different. The main distinction between the trials lies in
the average CHADS2 score, which was 2.1 in the ARISTOTLE
trial, 2.2 in the RE-LY trial, and 3.5 in the ROCKET-AF trial.7-9
The warfarin group in the ROCKET-AF trial also had less
optimal management of their INR readings, with only 55% of
patients within therapeutic range during the study, compared to
62% in ARISTOTLE and 64% in RE-LY.7-9 These factors could
contribute to the different results from these trials and preclude
clinicians from making direct comparisons without additional
real-world data.
In comparison to warfarin, apixaban is similar to the other
new anticoagulants in that it provides adequate anticoagulation
without the need for therapeutic monitoring or dietary
restrictions. However, the drawbacks to these new agents
include the lack of a reversal agent, no monitoring parameters
to determine medication compliance, and multiple daily
dosing with dabigatran and apixaban.3 There have also been no
studies evaluating the safety of apixaban in patients with renal
insufficiency or with long- term use. Compared to dabigatran and
rivaroxaban, apixaban offers the advantage of a lower bleeding
rate, fewer drug interactions, and less gastrointestinal side effects.
Therefore, apixaban is a promising new anticoagulant that will
offer an alternative to the currently available options.

Discussion
The two clinical trials, AVERROES and ARISTOTLE,
compared apixaban to aspirin and warfarin, respectively, and
demonstrated that apixaban significantly reduced the rate of
stroke in patients with atrial fibrillation and at least one risk
factor for stroke. Apixaban was also shown to not significantly
increase bleeding risk when compared to aspirin and showed
a significantly decreased risk of bleeding when compared to
warfarin.6,7
While apixaban appears to be superior to warfarin in terms
of efficacy and safety, there are no controlled trials that directly
compare apixaban to the other novel oral anticoagulants, such
as dabigatran or rivaroxaban.6,7 The ACCP guidelines have been
revised to favor dabigatran 150 mg twice daily over vitamin K
antagonists in patients with a CHADS2 score of two or more
based on the RE-LY (Randomized Evaluation of Long-Term
Anticoagulation Therapy) trial.2 This study demonstrated that
dabigatran 150 mg twice daily was superior to warfarin in the
prevention of stroke and systemic embolism in patients with
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